Emerging targeted therapies for breast cancer.
Targeted therapies offer a new approach to breast cancer treatment. Rather than eliminating both malignant and normal cells nonspecifically, these so-called "rational" therapies exploit second messenger proteins, ligands, and receptors that are known to be upregulated in neoplastic cells, or are implicated in cancer metastasis. This review will highlight a number of these targets and the mechanisms that have been targeted in drug design. We will also describe recently completed and currently ongoing clinical trials investigating targeted therapies and their potential to augment standard breast cancer therapy.
Johnson
Melissa L
ML
Joan and Sanford I. Weill Medical College, Cornell University, New York, New York, USA.
Seidman
Andrew D
AD
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use; D016172:DNA Fingerprinting / Q000379:methods; D005260:Female; D006801:Humans; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D016861:Cyclooxygenase Inhibitors; D020794:Receptor Protein-Tyrosine Kinases